MedTrace Logo

Remifentanil and Hyperalgesia: Gradual Withdrawal Versus Immediate Discontinuation

NCT03110653 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-10-18

No results posted yet for this study

Summary

Modern anesthesia has made a lot of progress, however, postoperative pain remains one of the major problems associated with patient discomfort, prolonged hospital stay and increased health care costs.

Remifentanil is an ultra-short-acting phenylpiperidine opioid analgesic with high lipid solubility and a rapid onset of effect.

Recently, opioid use has also been associated with postoperative opioid-induced hyperalgesia or acute opioid tolerance. An immediate discontinuation of remifentanil has been associated to increased postoperative pain levels.

We would like to investigate whether a gradual post-operative withdrawal of remifentanil is indeed associated with less immediate pain compared to after an abrupt withdrawal in surgical patients undergoing minor surgery.

Conditions

Interventions

DRUG

Remifentanil

Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)

DRUG

NaCl 0.9%

NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.

Sponsors & Collaborators

  • Université Libre de Bruxelles

    lead OTHER

Principal Investigators

  • Luc Barvais · Erasme Hospital, Brussels

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-15
Primary Completion
2017-08-30
Completion
2017-08-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03110653 on ClinicalTrials.gov